CN105687393A - Pharmaceutical composition for treating lung cancer - Google Patents

Pharmaceutical composition for treating lung cancer Download PDF

Info

Publication number
CN105687393A
CN105687393A CN201610047085.8A CN201610047085A CN105687393A CN 105687393 A CN105687393 A CN 105687393A CN 201610047085 A CN201610047085 A CN 201610047085A CN 105687393 A CN105687393 A CN 105687393A
Authority
CN
China
Prior art keywords
pharmaceutical composition
weight portion
weight
ethanol
percent concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610047085.8A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Xingyi Medical Technology Co Ltd
Original Assignee
Jinan Xingyi Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Xingyi Medical Technology Co Ltd filed Critical Jinan Xingyi Medical Technology Co Ltd
Priority to CN201610047085.8A priority Critical patent/CN105687393A/en
Publication of CN105687393A publication Critical patent/CN105687393A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a pharmaceutical composition for treating lung cancer and a preparation method thereof. The pharmaceutical composition is prepared from the following bulk pharmaceutical chemicals in proportion: dicranopteris linearis, northern bedstraw, trifolirhizin, maritimetin and andrographin glucoside E, can be prepared to various dosage forms according to a conventional preparation process, and has a remarkable effect in treating the lung cancer.

Description

The pharmaceutical composition for the treatment of pulmonary carcinoma
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition treating pulmonary carcinoma and preparation method thereof。
Background technology
Primary bronchogenic carcinoma of lung (primarybronchogeniccarcinoma) is called for short pulmonary carcinoma (lungcancer)。Tumor cell originates from bronchial mucosa or body of gland, is modal pulmonary primary malignant tumor。In China's urban population, the mortality rate of pulmonary carcinoma is leapt to the first place into various tumors by the 4th, and rising the fastest in rural area is also pulmonary carcinoma。The history of pulmonary carcinoma only had for more than 500 years。Within 1420, a mine in Germany Saxony is found that the first pulmonary carcinoma。Within 1875, see cancerous cell first at apoplexy due to phlegm。Some experts even predict that: if smoking and air pollution can not be efficiently controlled, more than 1,000,000, the first in the world pulmonary carcinoma big country will be become to the annual pulmonary carcinoma number of China in 2025。For Point of View of Clinical, pulmonary carcinoma can be divided into two classes: i.e. small cell lung cancer (smallcelllungcancer, SCLC) and nonsmall-cell lung cancer (non-smallcelllungcancer, NSCLC)。Its small cell lung cancer constitutes about the 25% of pulmonary carcinoma。Owing to cancerous tissue spreads rapidly, most patients lose the chance of surgical resection, and clinical course is usually no more than 3 months。And one of feature of tumor cell is abnormality proliferation, the propagation suppressing tumor cell is one of approach treating tumor, is also the basic demand of antitumor drug。Although without this name of disease of pulmonary carcinoma in motherland's medical science, but the clinical manifestation of " lump in the right hypochondrium " described in document is comparatively similar to pulmonary carcinoma, it is possible to be attributed to the category of diseases such as " cough " " phlegm retention " " lump in the right hypochondrium " " spitting of bloods "。Its main clinical manifestation: upper gas cough, dyspnea with rapid and short breath chest pain, expectoration is spat blood, uncomfortable in chest out of breath, and xerostomia of generating heat, shortness of breath and fatigue, waist soreness, fear of cold is afraid of cold。Along with becoming better and approaching perfection day by day of tcm theory and constantly accumulating of clinical experience, now explore gradually and define a new medical disciplines--there is the TCM Oncology of comparatively full theoretical system and determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs specification。Current pulmonary carcinoma Chinese traditional treatment is mainly used in the following aspects: (1) can not perform the operation or postoperative, recurrence after radiotherapy person for the nonsmall-cell lung cancer of good differentiation, and alone Chinese medicine can obtain more good effect than Radiotherapy chemotherapy；(2) coordinate operation, chemicotherapy, play synergism and attenuation, namely reduce toxicity, improve curative effect；(3) advanced lung cancer doctor trained in Western medicine is without special treatment person, and application Chinese medicine can improve symptom, improves life quality, extends life cycle, and has certain advantage in anti-recurrence transfer。
Wolf beanstalk grass: this product is Diplopterygium glaucum (Thunb ex Houtt) Nakai section Dicranopteris dichotoma platymiscium ferrum Dicranopteris dichotoma Dicranopterislinearis(Burm.f.) Underw. ［ PolypodiumlineareBurm.f.；GleichenialinearisClarke ］ herb。The whole year all can gather, and cleans, removes fibrous root and petiole, separated with leaf by rhizome, dry。[nature and flavor] are bitter；Sweet；Flat。[function cures mainly] stops blooding；Synthetism；Clearing away heat-damp and promoting diuresis；Removing toxic substances and promoting subsidence of swelling。Main metrorrhagia；Epistaxis；Hemoptysis；Traumatic hemorrhage；Injury and bone fracture；The puckery pain of pyretic stranguria；Leucorrhea；Rubella pruritus；Skin ulcer swells；Scald；Hemorrhoid complicated by anal fistula；Snake bite and insect sting；Cough。[former phytomorph] ferrum Dicranopteris dichotoma, large-scale terrestrial pteridophyta, plant height 60-150cm。Overgrow。Rhizome horizontal walk, dark-brown, children time base portion by brown hair, after polish；Rachis five to eight times two fork branch, a long 13-16cm of rachis, the pinna rachis of more than two times is shorter, and the long 3.5-6cm of rachis is returned at end；Each time axillalry bud is avette, close by rust hair；Tool bract, avette, edge tool triangle sliver；Except first time bifurcated, all there is 1 pair of stipule shape accessory pinna all the other each time crotch both sides, obliquely, the long 12-18cm of bottom, wide 3.2-4cm, diminishing of top, lanceolar or wide lanceolar；It is similar to stipule shape accessory pinna that accessory pinna is returned at end, long 5.5-15cm, wide 2.5-4cm, and comb dentation plumage splits and several reaches pinna rachis；Sliver 15-40 pair, lanceolar or wire lanceolar, long 10-18mm, wide 2-3mm, several to minimum on the upside of base portion, triangle, long 4-6mm；Middle arteries and veins is protruding below, and lateral vein is tiltedly opened up, and often group has scun 3, and sporangiorus is circular, tiny, 1 row, the tortuous bow place being born in scun on the upside of base portion, is made up of 5-7 Sporangium。Record in Chinese medicine voluminous dictionary。
Northern bedstraw: for the herb of Rubiaceae clivers Herba Galii borealis GaliumborealeL.。Autumn gathers, and cutting is dried。[nature and flavor] are bitter；Cold。[function cures mainly] heat-clearing and toxic substances removing；Expelling wind and activating blood circulation。Main pneumonia is coughed；Oedema due to nephritis；Lumbago and skelalgia；Women's amenorrhea；Dysmenorrhea；Leukorrhagia；Skin ulcer tinea。[chemical analysis] is containing quintessence oil, Coumarins, flavonoid and anthraquinone analog compound。[former phytomorph] Herba Galii borealis, perennial vertical herbage, high 20-50cm。Stem has four ribs, has branch, closely has microtriche without hair or joint portion。4, leaf is verticillate；Stockless；Blade wire lanceolar, long 1-3.5cm, wide 2-4mm, tip is blunt, the wealthy wedge shape of base portion or subcircular, and edge is warp slightly。Base goes out 3, arteries and veins, and flash trimming edge has outside microtriche, and two without hair。Cyme top is raw, or forms the panicle shape with leaf at Zhi Ding；Hua Mi, little, yellow-white；The long 3-5mm of pedicel；Sepal 4, ellipticity is avette, has thin hair, and tip is short tapering；Stamen 4, with sepal alternate；Ovary is the next, and subsphaeroidal, style 2 splits to nearly base portion。Fruit is spherical, little, black, close by white glochild。The month at florescence 6-8, fruit month phase 7-9。Record in Chinese medicine voluminous dictionary。
Coreopsis basalis (Maritimetin): CAS 576-02-3, molecular formula C15H10O6, molecular weight 286.24。[pharmacological action] desiodothyroxine takes off iodine enzyme inhibitor。In [ingredient origin] Compositae strand Coreopsis basalis and gold dish silver plate Hemerocallis citrina Baroni。
Andrographin glycosides E (AndrographidineE): CAS 113963-41-0, molecular formula C24H26O11, molecular weight 490.47。[ingredient origin] Herba Andrographis Andrographispaniculata [Syn.paniculata]。
Trifolirhizin (Trifolirhizin): CAS 6807-83-6, molecular formula C22H22O10, molecular weight 446.40。[pharmacological action] has antibacterial action。The antitumaous effect of this product relatively other aglycons are strong, but more weak than its dextrorotation。[ingredient origin] Herba Trifolii Pratentis Trifoliumpratense, Radix Sophorae Tonkinensis Sophorasubprostrata ［ Syn.Sophoratonkinensis ］。
3 crude drug chemical constitutions:
Andrographin glycosides E (AndrographidineE)
Coreopsis basalis (Maritimetin) trifolirhizin (Trifolirhizin)。
Summary of the invention
It is an object of the invention to overcome the deficiency of background technology, it is provided that pharmaceutical composition of a kind of effective treatment pulmonary carcinoma and preparation method thereof。
The present invention adopts the following technical scheme that realization:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment pulmonary carcinoma be:
Wolf beanstalk grass 3080-3090 weight portion northern bedstraw 2220-2230 weight portion trifolirhizin 165-170 weight portion Coreopsis basalis 210-216 weight portion andrographin glycosides E180-200 weight portion。
It is preferably used in the pharmaceutical composition for the treatment of pulmonary carcinoma, is prepared by the crude drug composition of weight portion:
Wolf beanstalk grass 3085 weight portion northern bedstraw 2225 weight portion trifolirhizin 167 weight portion Coreopsis basalis 213 weight portion andrographin glycosides E190 weight portions。
A kind of pharmaceutical composition treating pulmonary carcinoma, it is characterised in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare into tablet or capsule or drop pill。
A kind of pharmaceutical composition treating pulmonary carcinoma, it is characterised in that the treatment lung-cancer medicament that pharmaceutical composition forms with chemical drugs or Chinese medicine。
The preparation method of a kind of pharmaceutical composition treating pulmonary carcinoma, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: wolf beanstalk grass 3080-3090 weight portion northern bedstraw 2220-2230 weight portion trifolirhizin 165-170 weight portion Coreopsis basalis 210-216 weight portion andrographin glycosides E180-200 weight portion；
Preparation method:
(1) wolf beanstalk grass is taken by crude drug proportioning, northern bedstraw, trifolirhizin, Coreopsis basalis, andrographin glycosides E, mixing, with weight percent concentration 19% ethanol as solvent, extract at 28.5 DEG C of warm macerating, extraction time is 14 times, each extraction time is 22 hours, each solvent load is 22 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.08, filter, medicinal liquid passes through D4020 macroporous adsorptive resins, first wash with water, again with weight percent concentration 39.5% alcoholic solution eluting D4020 macroporous adsorptive resins, collect weight percent concentration 39.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 45% ethanol as solvent, heating and refluxing extraction 9 times, each extraction time is 0.4 hour, each solvent load is 40 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.18, filter, medicinal liquid passes through LK07 macroporous adsorptive resins, first wash with water, again with weight percent concentration 66% alcoholic solution eluting LK07 macroporous adsorptive resins, collect weight percent concentration 66% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition。
The preferably preparation method of a kind of pharmaceutical composition treating pulmonary carcinoma, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: wolf beanstalk grass 3085 weight portion northern bedstraw 2225 weight portion trifolirhizin 167 weight portion Coreopsis basalis 213 weight portion andrographin glycosides E190 weight portions；
Preparation method:
(1) wolf beanstalk grass is taken by crude drug proportioning, northern bedstraw, trifolirhizin, Coreopsis basalis, andrographin glycosides E, mixing, with weight percent concentration 19% ethanol as solvent, extract at 28.5 DEG C of warm macerating, extraction time is 14 times, each extraction time is 22 hours, each solvent load is 22 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.08, filter, medicinal liquid passes through D4020 macroporous adsorptive resins, first wash with water, again with weight percent concentration 39.5% alcoholic solution eluting D4020 macroporous adsorptive resins, collect weight percent concentration 39.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 45% ethanol as solvent, heating and refluxing extraction 9 times, each extraction time is 0.4 hour, each solvent load is 40 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.18, filter, medicinal liquid passes through LK07 macroporous adsorptive resins, first wash with water, again with weight percent concentration 66% alcoholic solution eluting LK07 macroporous adsorptive resins, collect weight percent concentration 66% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition。
The preparation method of a kind of pharmaceutical composition treating pulmonary carcinoma, it is characterised in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare into tablet or capsule or drop pill。
The preparation method of a kind of pharmaceutical composition treating pulmonary carcinoma, it is characterised in that pharmaceutical composition and chemical drugs or Chinese medicine composition treatment lung-cancer medicament。
Medicine composite for curing pulmonary carcinoma is evident in efficacy。
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of pulmonary carcinoma and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of pulmonary carcinoma be: wolf beanstalk grass 3085g northern bedstraw 2225g trifolirhizin 167g Coreopsis basalis 213g andrographin glycosides E190g；
Preparation method:
(1) wolf beanstalk grass is taken by crude drug proportioning, northern bedstraw, trifolirhizin, Coreopsis basalis, andrographin glycosides E, mixing, with weight percent concentration 19% ethanol as solvent, extract at 28.5 DEG C of warm macerating, extraction time is 14 times, each extraction time is 22 hours, each solvent load is 22 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.08, filter, medicinal liquid passes through D4020 macroporous adsorptive resins, first wash with water, again with weight percent concentration 39.5% alcoholic solution eluting D4020 macroporous adsorptive resins, collect weight percent concentration 39.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 45% ethanol as solvent, heating and refluxing extraction 9 times, each extraction time is 0.4 hour, each solvent load is 40 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.18, filter, medicinal liquid passes through LK07 macroporous adsorptive resins, first wash with water, again with weight percent concentration 66% alcoholic solution eluting LK07 macroporous adsorptive resins, collect weight percent concentration 66% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition。
Embodiment 2: pharmaceutical composition for the treatment of pulmonary carcinoma and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of pulmonary carcinoma be: wolf beanstalk grass 3080g northern bedstraw 2230g trifolirhizin 165g Coreopsis basalis 216g andrographin glycosides E180g；
Preparation method:
(1) wolf beanstalk grass is taken by crude drug proportioning, northern bedstraw, trifolirhizin, Coreopsis basalis, andrographin glycosides E, mixing, with weight percent concentration 19% ethanol as solvent, extract at 28.5 DEG C of warm macerating, extraction time is 14 times, each extraction time is 22 hours, each solvent load is 22 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.08, filter, medicinal liquid passes through D4020 macroporous adsorptive resins, first wash with water, again with weight percent concentration 39.5% alcoholic solution eluting D4020 macroporous adsorptive resins, collect weight percent concentration 39.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 45% ethanol as solvent, heating and refluxing extraction 9 times, each extraction time is 0.4 hour, each solvent load is 40 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.18, filter, medicinal liquid passes through LK07 macroporous adsorptive resins, first wash with water, again with weight percent concentration 66% alcoholic solution eluting LK07 macroporous adsorptive resins, collect weight percent concentration 66% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition。
Embodiment 3: pharmaceutical composition for the treatment of pulmonary carcinoma and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of pulmonary carcinoma be: wolf beanstalk grass 3090g northern bedstraw 2220g trifolirhizin 170g Coreopsis basalis 210g andrographin glycosides E200g；
Preparation method:
(1) wolf beanstalk grass is taken by crude drug proportioning, northern bedstraw, trifolirhizin, Coreopsis basalis, andrographin glycosides E, mixing, with weight percent concentration 19% ethanol as solvent, extract at 28.5 DEG C of warm macerating, extraction time is 14 times, each extraction time is 22 hours, each solvent load is 22 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.08, filter, medicinal liquid passes through D4020 macroporous adsorptive resins, first wash with water, again with weight percent concentration 39.5% alcoholic solution eluting D4020 macroporous adsorptive resins, collect weight percent concentration 39.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 45% ethanol as solvent, heating and refluxing extraction 9 times, each extraction time is 0.4 hour, each solvent load is 40 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.18, filter, medicinal liquid passes through LK07 macroporous adsorptive resins, first wash with water, again with weight percent concentration 66% alcoholic solution eluting LK07 macroporous adsorptive resins, collect weight percent concentration 66% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition。
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 257g, adds starch 157g, mixing, granulates, dry, adds microcrystalline Cellulose 57g, magnesium stearate 4g, and mixing is pressed into 1300, obtains medicinal composition tablets。
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 240g, adds starch 240g, mixing, granulates, dry, and granulate adds appropriate magnesium stearate, mixing, encapsulated 1200, obtains medicament composition capsule。
Embodiment 6: the preparation of drop pill
Weigh polyethylene glycol 6000 335g water-bath (80 DEG C) heating and boil molten, add embodiment 3 pharmaceutical composition 12g, stir, with liquid paraffin for coolant, put in glass tubing (4*80cm), chilling temperature is 5 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 2.1cm from liquid level, drips speed with per minute 60 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills。
Embodiment 7: the pharmaceutical composition for the treatment of pulmonary carcinoma
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of pulmonary carcinoma be:
Trifolirhizin 290 weight portion Coreopsis basalis 240 weight portion andrographin glycosides E80 weight portion。
Embodiment 8: the pharmaceutical composition for the treatment of pulmonary carcinoma
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of pulmonary carcinoma be:
Trifolirhizin 240 weight portion Coreopsis basalis 175 weight portion andrographin glycosides E215 weight portion。
Embodiment 9: the pharmaceutical composition for the treatment of pulmonary carcinoma
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of pulmonary carcinoma be:
Trifolirhizin 146 weight portion Coreopsis basalis 202 weight portion andrographin glycosides E78 weight portion。
Experimental example 1: the experimental study for the treatment of pulmonary carcinoma
1 material
1.1 medicines
Pharmaceutical composition (embodiment 1 pharmaceutical composition lot number 20050712)。
1.2 positive control medicines
Jin Xisu (hydrochloride for injection hycamtin), Guizhou hanfang Pharmaceutical Co., Ltd, authentication code: the quasi-word H20000428 specification of traditional Chinese medicines: 2mg/ bottle。
1.3 people's lung small cell lung cancer NCI-H446 cell strains
People's lung small cell lung cancer NCI-H446 cell strain is bought in Nanjing KaiJi Biology Science Development Co., Ltd, fostering requirement: adhere-wall culture:
Culture medium: RPMI-1640+10% calf serum+1% is dual anti-
Digestive system: 0.25% trypsin
Frozen stock solution: hyclone: DMSO=9:1
Condition of culture: CO2 gas incubator: 5%CO2,37℃。
2 methods
2.1 medications
2.1.1 pharmaceutical composition, is dissolved in water, and is configured to the solution of concentration 0.5g/ml, and then through autoclave sterilizer sterilizing, 4 DEG C of refrigerators are deposited standby。
2.1.2 gold happiness element (hydrochloride for injection hycamtin) the every consumption per day of human body: 1.2mg/m2。
The cultivation of 2.2 people's lung small cell lung cancer NCI-H446 cells
2.2.1 cellular identification
The cell strain received is identified, full-time pathology teacher under inverted microscope, observes qualification, and in conjunction with the cell data that Nanjing KaiJi Biology Science Development Co., Ltd provides, be accredited as NCI-H446 cell strain。
After cell strain receives, Tissue Culture Flask stands intact, and culture fluid is without extravasation, and culture fluid is without muddiness。Observation of cell density under inverted microscope, degree of converging is about 60%, not up to the requirement of the degree of converging 80% that passage requires, by culture fluid sucking-off in culture bottle, stays 10ml culture fluid to continue to cultivate, and cellular morphology presents circle or shuttle。Crossed after 2d cell confluency degree more than 80% after, go down to posterity by passage requirement。Cell high malignancy, undifferentiated。Cancer cell size is little, and core is circular and oval, and cancerous cell endochylema is few, and caryoplasm ratio significantly increases, and core profile is irregular, and karyokinesis is common, and cancerous cell boundary is unclear。
2.2.2 passage
Continue to cultivate cell, until when cell confluency degree reaches the requirement that passage is 80%, carrying out passage。In NCI-H446 cell bottle, add 0.25% trypsin, digest 3-6min, add culture medium piping and druming, be fabricated to cell suspension and go down to posterity by 1:2。
Going down to posterity by cell culture condition, after 3 Secondary Culture, cell one has 8 bottles。Cellular morphology presents circle or shuttle, frozen by wherein 4 bottles。Be used for subsequent experimental by 2 bottles, other 2 bottles are continued Secondary Culture。
2.3 cell growth curves are drawn
2.3.1 cell application of sample calculates cell concentration 2 times, draws cell concentration meansigma methods。Then by each hole adding culture plate of cell suspension equivalent, observing 4 holes every day, incubation time is calculated as 7d。
2.3.2 observation index sucks the culture fluid in 4 holes every 24h, adds Digestive system, suspendible cell, counting cells number。Each hole counts 2 times, draws cell concentration meansigma methods。
2.3.3 drawing cell growth curve abscissa is incubation time, and vertical coordinate is cell concentration, draws cell growth curve。Cell doubling time is about 26h。
2.4 cell growth inhibition assays
2.4.1 cell application of sample is taken the logarithm the cell of trophophase, and cell makes cell suspension, then cell suspension is added cell counting count board counts, and is formulated as 5000/ml cell concentration, by its inoculating cell culture plate。The 96 every hole 100 μ l of porocyte culture plate put into 37 DEG C, 5%CO2Incubator continues to cultivate。
2.4.2 cultivate through 24h after adding method thereof cell application of sample, 96 porocyte culture plates are taken out from CO2 gas incubator, by inverted microscope observation of cell form, it is determined that after Growth of Cells is good, empirically the every hole of packet sampler adds each 5 μ l of respective liquid。The often multiple hole of group 4。
2.4.3, after detection method is cultivated then through 24h, 96 porocyte culture plates add MTT solution 10 μ l and continues to cultivate 4h。Suck culture fluid, add and the same amount of DMSO of culture fluid。Then vibrate 10min, makes crystallization fully dissolve。Enzyme-linked immunosorbent assay instrument measures absorbance value。
2.4.4 the pharmaceutical composition IC that experiment packet is obtained according to pharmaceutical composition cellulotoxic experiment50Value, draws the IC of pharmaceutical composition50The administration concentration scope at value place。This experiment IC50The administration concentration scope at value place is between 1-100 μ g/ml。Therefore experiment is grouped as follows:
Pharmaceutical composition group: the intermediate concentration (50 μ g/ml) of compositions group of getting it filled；
Pharmaceutical composition adds Western medicine group: the intermediate concentration (50 μ g/ml) of compositions group of getting it filled also adds and uses Western medicine；
Western medicine group；
Blank group (only adds cell culture fluid), totally 4 big group, each group of each 4 multiple holes。
2.4.5 observation index measures absorbance value in microplate reader, and mensuration wavelength is 490nm, measures OD numerical value。And carry out morphological observation。
2.4.6 drawing cell growth inhibition assay chart cell survival rate (%)=experimental group absorbance value/matched group absorbance value × 100%, matched group is that the cell culture fluid only adding equivalent is not added with any medicine。Cell proliferation inhibition rate (%)=(1-cell survival rate) × 100%。With the time for transverse axis, with cell proliferation inhibition rate for the longitudinal axis, draw cell growth inhibition assay chart。
2.5 experiment conditions control all experiments to be completed in central laboratory of Zunyi Medical College, and cell is cultivated and coherent detection completes at its cell culture chamber。
2.6 statistical procedures method variance analysis comparison in difference between two LSD-t checks, and compares between the two and compares with mean。Statistics software application MicrosoftExcel2000 carries out statistical analysis。
3 results
The 3.1 variable concentrations pharmaceutical compositions inhibited proliferation to NCI-H446 cell
Human small cell lung carcinoma NCI-H446 cell is in 5 concentration of 10,25,50,75,100 μ g/ml, and cancerous cell presents corresponding change: namely along with the cancer cell number that increases of pharmaceutical composition drug level significantly reduces。NCI-H446 cell is when low concentration 25 μ g/ml, and the maximum cancerous cell of cell quantity is mutually overstock and presents deformation state。NCI-H446 cell is when higher concentration 75 μ g/ml, and cancerous cell is oval, fusiformis；Core is big, endochylema is few；Kernel is inconspicuous, and karyokinesis is inconspicuous。NCI-H446 cell is when higher concentration 100 μ g/ml, and cell quantity continues to reduce, and cancerous cell is that structure is unclear。
3.2 with the acute drug compositions proliferation inhibition rate to NCI-H446 cell
Pharmaceutical composition is in the 10,25,50,75,100 each concentration of μ g/ml and compares with blank group (medium controls) at these 3 observation time points of 24,48,72h and all has significant difference。
Pharmaceutical composition group repeats experiment for 3 times and obtains through statistical analysis: P=0.456, and namely pharmaceutical composition repeats experiment no difference of science of statistics for 3 times, and illustrative experiment has repeatability。The propagation of NCI-H446 cell is had obvious inhibitory action by result display variable concentrations pharmaceutical composition effect 48h, and along with the prolongation inhibitory action of action time weakens gradually, and along with the increase of dosage, inhibitory action strengthens。Pharmaceutical composition respectively reaches 63.18%, 66.35% and 35.24% at the suppression ratio of 24,48,72h。The highest suppression ratio of the pharmaceutical composition of 3 experiments respectively reaches 66.35%, 63.46% and 58.37%。
Comparison between 3.3 4 administration groups (pharmaceutical composition group, pharmaceutical composition add Western medicine group, Western medicine group, blank group)
3.3.1 morphological observation
The intermediate concentration (50 μ g/ml) that pharmaceutical composition group is selected。Human small cell lung carcinoma NCI-H446 cell presents different cellular morphology under 4 kinds of different modes of administration effects。Wherein to add Western medicine group effect on 48h point of observation the most obvious for pharmaceutical composition, and the complete pyknosis of nucleus, karyolysis, cell outline is difficult to recognize；Next to that Western medicine group, cell presents karyopyknosis, karyolysis, and cell outline can be recognized reluctantly；Being Chinese drug-treated group again, cell presents karyopyknosis once in a while, and cell outline is clear, and the maximum cancerous cell of cell quantity is mutually overstock and presents deformation state, and cancerous cell is oval, fusiformis but irregular；It is good that blank goes out cell survival conditions, and core is big, endochylema is few；Kernel is inconspicuous, and karyokinesis enlivens, and simply has senile cell to increase once in a while。
3.3.2 the different modes of administration proliferation inhibition rate to NCI-H446 cell
The intermediate concentration (50 μ g/ml) that pharmaceutical composition group is selected。Pharmaceutical composition adds Western medicine group and pharmaceutical composition group；Pharmaceutical composition adds Western medicine group and Western medicine group；Pharmaceutical composition group and Western medicine group；Pharmaceutical composition group and blank group；Pharmaceutical composition adds Western medicine group and blank group；The cell inhibitory rate of Western medicine group and blank group has significant difference。Compared between two by mean between administration group: pharmaceutical composition adds Western medicine group and is better than pharmaceutical composition group；Pharmaceutical composition adds Western medicine group and is better than Western medicine group；Western medicine group is better than pharmaceutical composition group；Pharmaceutical composition group is better than blank group；Pharmaceutical composition adds Western medicine group and is better than blank group；Western medicine group is better than blank group and has significant difference。
It is shown that pharmaceutical composition is inhibited to people's lung small cell lung cancer NCI-H446 cell in vitro, there is potential medical value, be worth further investigation further。

Claims (8)

1. the pharmaceutical composition treating pulmonary carcinoma, it is characterised in that composition and the weight portion of making the crude drug of this pharmaceutical composition be:
Wolf beanstalk grass 3080-3090 weight portion northern bedstraw 2220-2230 weight portion trifolirhizin 165-170 weight portion Coreopsis basalis 210-216 weight portion andrographin glycosides E180-200 weight portion。
2. a kind of pharmaceutical composition treating pulmonary carcinoma according to claim 1, it is characterised in that composition and the weight portion of making the crude drug of this pharmaceutical composition be:
Wolf beanstalk grass 3085 weight portion northern bedstraw 2225 weight portion trifolirhizin 167 weight portion Coreopsis basalis 213 weight portion andrographin glycosides E190 weight portions。
3. a kind of pharmaceutical composition treating pulmonary carcinoma according to claim 1, it is characterised in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare into tablet or capsule or drop pill。
4. a kind of pharmaceutical composition treating pulmonary carcinoma according to claim 1, it is characterised in that the treatment lung-cancer medicament of pharmaceutical composition and chemical drugs or Chinese medicine composition。
5. the preparation method of the pharmaceutical composition treating pulmonary carcinoma, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: wolf beanstalk grass 3080-3090 weight portion northern bedstraw 2220-2230 weight portion trifolirhizin 165-170 weight portion Coreopsis basalis 210-216 weight portion andrographin glycosides E180-200 weight portion；
Preparation method:
(1) wolf beanstalk grass is taken by crude drug proportioning, northern bedstraw, trifolirhizin, Coreopsis basalis, andrographin glycosides E, mixing, with weight percent concentration 19% ethanol as solvent, extract at 28.5 DEG C of warm macerating, extraction time is 14 times, each extraction time is 22 hours, each solvent load is 22 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.08, filter, medicinal liquid passes through D4020 macroporous adsorptive resins, first wash with water, again with weight percent concentration 39.5% alcoholic solution eluting D4020 macroporous adsorptive resins, collect weight percent concentration 39.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 45% ethanol as solvent, heating and refluxing extraction 9 times, each extraction time is 0.4 hour, each solvent load is 40 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.18, filter, medicinal liquid passes through LK07 macroporous adsorptive resins, first wash with water, again with weight percent concentration 66% alcoholic solution eluting LK07 macroporous adsorptive resins, collect weight percent concentration 66% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition。
6. the preparation method of a kind of pharmaceutical composition treating pulmonary carcinoma according to claim 5, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: wolf beanstalk grass 3085 weight portion northern bedstraw 2225 weight portion trifolirhizin 167 weight portion Coreopsis basalis 213 weight portion andrographin glycosides E190 weight portions；
Preparation method:
(1) wolf beanstalk grass is taken by crude drug proportioning, northern bedstraw, trifolirhizin, Coreopsis basalis, andrographin glycosides E, mixing, with weight percent concentration 19% ethanol as solvent, extract at 28.5 DEG C of warm macerating, extraction time is 14 times, each extraction time is 22 hours, each solvent load is 22 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.08, filter, medicinal liquid passes through D4020 macroporous adsorptive resins, first wash with water, again with weight percent concentration 39.5% alcoholic solution eluting D4020 macroporous adsorptive resins, collect weight percent concentration 39.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 45% ethanol as solvent, heating and refluxing extraction 9 times, each extraction time is 0.4 hour, each solvent load is 40 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.18, filter, medicinal liquid passes through LK07 macroporous adsorptive resins, first wash with water, again with weight percent concentration 66% alcoholic solution eluting LK07 macroporous adsorptive resins, collect weight percent concentration 66% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition。
7. the preparation method of a kind of pharmaceutical composition treating pulmonary carcinoma according to claim 5, it is characterised in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare into tablet or capsule or drop pill。
8. the preparation method of a kind of pharmaceutical composition treating pulmonary carcinoma according to claim 5, it is characterised in that pharmaceutical composition and chemical drugs or Chinese medicine composition treatment lung-cancer medicament。
CN201610047085.8A 2016-01-25 2016-01-25 Pharmaceutical composition for treating lung cancer Withdrawn CN105687393A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610047085.8A CN105687393A (en) 2016-01-25 2016-01-25 Pharmaceutical composition for treating lung cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610047085.8A CN105687393A (en) 2016-01-25 2016-01-25 Pharmaceutical composition for treating lung cancer

Publications (1)

Publication Number Publication Date
CN105687393A true CN105687393A (en) 2016-06-22

Family

ID=56229292

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610047085.8A Withdrawn CN105687393A (en) 2016-01-25 2016-01-25 Pharmaceutical composition for treating lung cancer

Country Status (1)

Country Link
CN (1) CN105687393A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108295118A (en) * 2017-12-27 2018-07-20 济南昊雨青田医药技术有限公司 A kind of limonin method for preparing extractive for treating lung cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108295118A (en) * 2017-12-27 2018-07-20 济南昊雨青田医药技术有限公司 A kind of limonin method for preparing extractive for treating lung cancer

Similar Documents

Publication Publication Date Title
CN105560608A (en) Pharmaceutical composition for treating lung cancer
CN106668348A (en) Pharmaceutical composition for treating diabetic retinopathy
CN105687393A (en) Pharmaceutical composition for treating lung cancer
CN1824077B (en) Chinese medicinal liquid capsule for treating gynecopathy and its preparation method
CN105031329A (en) Traditional Chinese medicine preparation used for treating liver qi stagnation-type hemicranias, and preparation method thereof
CN106692224A (en) Pharmaceutical composition for treatment of colpitis
CN106074736A (en) A kind of pharmaceutical composition treating cerebral thrombosis and preparation method thereof
CN105267448A (en) Medicine composition for treating chronic prostatitis
CN105535058A (en) Medicine composition for preventing and treating pancreatic cancer
CN105250467A (en) Medicine composition for treating chronic prostatitis
CN106727851A (en) Prevent and treat pharmaceutical composition of ovarian cyst and preparation method thereof
CN106540089A (en) Pharmaceutical composition for the treatment of rheumatoid arthritiss and preparation method thereof
CN106728628A (en) Treat the pharmaceutical composition of canker sore
CN105560867A (en) Medicine composition for treating schizophrenia and preparation method thereof
CN105616711A (en) Medicine composition for preventing and treating schizophrenia
CN105560487A (en) Medicine composition for preventing and treating coronary heart disease and preparation method thereof
CN106822389A (en) A kind of pharmaceutical composition for preventing and treating ovarian cyst
CN106668239A (en) Pharmaceutical composition for preventing vitreous opacity
CN106728467A (en) A kind of pharmaceutical composition for preventing and treating climacteric metancholia
CN106727842A (en) Treat pharmaceutical composition of cervicitis and preparation method thereof
CN106581263A (en) Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof
CN106668106A (en) Pharmaceutical composition for preventing and treating synovitis and preparation method thereof
CN106581529A (en) Medicine composition for treating pyelonephritis and preparation method of medicine composition
CN106581095A (en) Medicinal composition for treating neurodermatitis
CN106822340A (en) A kind of pharmaceutical composition of anti-treating cervicitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20160622